Abstract
Doxorubicin, ellipticine and etoposide are antineoplastic drugs with topoisomerase II inhibitory activity. The relationship between drug-induced sister-chromatid exchanges (SCEs) or chromosomal aberrations (CAs) and cytotoxicity, or drug-induced DNA double-strand breaks (DSBs) and cytotoxicity, or drug-induced SCEs and DSBs was investigated in human ovarian cancer cells sensitive (A2780) and resistant (A2780-DX3) to topoisomerase II inhibitors. 30-min drug treatments produced SCEs, CAs and DSBs in sensitive cells, doxorubicin being more potent than etoposide at equimolar concentrations. The same treatments of resistant (A2780-DX3) cells did not produce chromosomal damage (SCEs, CAs, DSBs) and no cytotoxicity was observed. A plot of cytotoxicity versus SCEs indicated a good correlation between these two parameters for topoisomerase II inhibitors and not for mytomicin C. The plot of DSBs versus SCEs also showed a very good correlation.
References
Oct 19, 1976·Biochemistry·K W KohnC A Friedman
May 16, 1978·Chromosoma·K GotoT Sugiyama
Nov 1, 1992·Japanese Journal of Cancer Research : Gann·G OrengoP Russo
Oct 1, 1991·Carcinogenesis·P RussoY Pommier
Jun 1, 1989·Mutation Research·F Darroudi, A T Natarajan
Nov 1, 1989·Mutation Research·L E DillehayJ R Williams
Dec 17, 1989·Biochimica Et Biophysica Acta·P D'Arpa, L F Liu
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M A Alaoui JamaliY M Rustum
Jan 14, 1986·Biochemistry·J MinfordL A Zwelling
Sep 13, 1974·Nature·P Perry, S Wolff
Jan 1, 1993·Environmental and Molecular Mutagenesis·F Palitti
Citations
Jul 3, 1997·International Journal of Cancer. Journal International Du Cancer·F VikhanskayaP Russo
May 13, 1999·Teratogenesis, Carcinogenesis, and Mutagenesis·M C AraújoC S Takahashi
Jan 5, 2002·Teratogenesis, Carcinogenesis, and Mutagenesis·Nevenka KopjarIvan Milas
Jan 1, 1995·Journal of Cancer Research and Clinical Oncology·G CimoliP Russo
Oct 9, 1998·Il Farmaco·M G FerlinF Bordin
Sep 28, 2000·European Journal of Medicinal Chemistry·M G FerlinF Bordin
Sep 24, 2002·Toxicology Letters·A Hernández-CeruelosC de la Cruz
Sep 2, 2003·Mutation Research·Mauricio LehmannHeloísa Helena Rodrigues de Andrade
Feb 26, 1999·Mutation Research·C MarzanoF Bordin
Apr 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·George Hong, Kenneth N Kreuzer
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·N A BergerS R Helms
Aug 16, 2011·Pharmacology & Therapeutics·Rene KizekMarie Stiborova
Jun 26, 2010·Biochimica Et Biophysica Acta·M StiborováE Frei
May 8, 2007·Toxicology·Marie StiborováEva Frei
Aug 28, 2004·Toxicology Letters·I Alvarez-GonzálezJ J Espinosa-Aguirre
Apr 4, 2006·Toxicology·C PrahalathanR Saravanan
Sep 7, 2012·PLoS Genetics·Masakazu HamadaJan M van Deursen
Nov 6, 2004·Gene·Deepa SaxenaShu-Wing Ng
Jan 1, 1997·Environmental and Molecular Mutagenesis·C MarzanoF Bordin
Mar 25, 2000·Photochemistry and Photobiology·C MarzanoF Bordin
Jun 18, 2002·Journal of Cellular and Molecular Medicine·C MarzanoF Bordin
Sep 16, 2006·The Journal of Biological Chemistry·Ailing ZhangLeroy F Liu